A
Alector, Inc. (ALEC)
NMS – Real Time Price. Currency in USD
2.16
+0.11 (5.37%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
2.16
+0.11 (5.37%)
At close: May 12, 2026, 4:00 PM EDT
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer’s disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson’s disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Arnon Rosenthal Ph.D. | Co-Founder, CEO & Director |
| Dr. Eric Brown Ph.D. | Director of Antibody Discovery & Protein Engineering |
| Dr. Hua Long DABT, Ph.D. | Senior VP & Head of Research |
| Mr. Giacomo Salvadore M.D. | Chief Medical Officer |
| Mr. Neil Berkley M.B.A., M.S. | CFO & Chief Business Officer |
| Ms. Clare Hunt M.B.A. | Chief People & Places Officer |
| Ms. Danielle Pasqualone J.D., Ph.D. | General Counsel |
| Ms. Katie Hogan | Senior Director of Corporate Communication & Investor Relations |
| Ms. Kristina Cutter M.P.H. | Chief Development Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | d910893d8k.htm |
| 2026-04-28 | DEFA14A | alec-20260422.htm |
| 2026-03-12 | S-3 | d907433ds3.htm |
| 2026-02-25 | S-8 | alec-20260225.htm |
| 2026-02-25 | 8-K | alec-20260225.htm |
| 2025-12-12 | 8-K | alec-20251210.htm |
| 2025-11-06 | 8-K | alec-20251106.htm |
| 2025-10-21 | 8-K | alec-20251020.htm |
| 2025-08-07 | 10-Q | alec-20250630.htm |
| 2025-06-13 | 8-K | d58708d8k.htm |